Employees: 39
Size Lumosa Therapeutics (6535.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $406M, the 508th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$83.30 on 18 Nov 2026.
Performance Over six months the shares fell 36.9%, against -17.2% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue fell 24.8% over the last twelve months (peer median +3.4%); the operating margin is -803.3% (peer median 4.6%).
Valuation It trades at 399.1× enterprise value to sales against a peer median of 3.7× (most expensive of 18).
Capital Return on invested capital runs 39.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$32.0M | NT$35.8M | NT$39.2M | NT$56.9M | NT$26.6M |
| Revenue growth | — | -8% | -31% | +114% | — |
| Gross profit | NT$15.7M | NT$21.8M | NT$17.6M | NT$24.8M | -NT$2.08M |
| EBITDA | -NT$247M | -NT$322M | -NT$349M | -NT$352M | -NT$284M |
| Net income | -NT$395M | -NT$341M | -NT$425M | -NT$238M | -NT$495M |
| Free cash flow | -NT$237M | -NT$357M | -NT$293M | -NT$335M | -NT$303M |
| Capital expenditure | NT$0 | NT$668,000 | NT$450,000 | NT$15.0M | NT$2.29M |
| Total debt | NT$1.74M | NT$6.92M | NT$8.48M | NT$12.6M | NT$4.69M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6535.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.8% | -11.1% | 3rd highest of 21 |
| 6-month return | -36.9% | -17.2% | 5th lowest of 20 |
| Distance from 52-week high | -62.5% | -42.0% | 5th lowest of 21 |
| Revenue growth (TTM) | -24.8% | +3.4% | 3rd lowest of 19 |
| Operating margin | -803.3% | 4.6% | 2nd lowest of 19 |
| EV / Sales | 399.1× | 3.7× | most expensive of 18 |
| ROIC minus cost of capital | -39.4 pp | -1.4 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lumosa Therapeutics 6535.TWO | Taiwan | $406M | -37% | -25% | -803% | 399.1× | n/a | n/a |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $406M | -18% | -16% | 2% | 1.9× | 9.2% | +6.7% |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $407M | -15% | -16% | 7% | 1.7× | -3.2% | +11.2% |
| Shandong Sinobioway Biomedicine 002581.SZ | China | $405M | -24% | +91% | -65% | 7.9× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $410M | -49% | -88% | -676% | 4.7× | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $398M | -13% | -3% | 2% | 3.4× | 14.9% | +13.7% |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 3.2× | 24.4% | +8.0% |
| Heartseed 219A.T | Japan | $392M | +53% | +197% | 9% | 21.9× | 46.5% | +73.2% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | 7.1× | n/a | n/a |
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $388M | -17% | +9% | 19% | 2.2× | -5.5% | +12.2% |
| Avalo Therapeutics AVTX | United States | $387M | -59% | -69% | -161,961% | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |